1. The study evaluated patients who had surgery with the device for symptomatic degenerative disc disease and spinal stenosis.
2. Analyses of the patients at six-months found sustained improvement in clinical efficacy and safety compared to three-month evaluations.
3. Reserachers concluded, “This 6-month interim analysis at 42% enrollment of patients was conducted to determine prolonged safety and efficacy of the interspinous fusion device. Our analysis showed a sustained improvement in clinical efficacy, and safety endpoints, when compared to the 3-months evaluations, across both interventional pain and neurosurgery specialties.”
4. The Zip system was cleared by the FDA inn 2013 and went to market in 2014.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
